Long-term Evaluation of Residual Viremia in a Clinical Trial of Dolutegravir Plus Lamivudine as Maintenance Treatment for Participants With and Without Prior Lamivudine Resistance
© The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America..
In this pilot clinical trial, we evaluated rates of residual replication in persons without lamivudine resistance-associated mutations in proviral DNA population sequencing who switched to dolutegravir plus lamivudine. After 144 weeks, there was no signal of changes in residual viremia based on qualitative detection methods, irrespective of past lamivudine resistance. Clinical Trials Registration. NCT03539224.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:9 |
|---|---|
| Enthalten in: |
Open forum infectious diseases - 9(2022), 11 vom: 01. Nov., Seite ofac610 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
De Miguel Buckley, Rosa [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Dolutegravir plus lamivudine |
|---|
| Anmerkungen: |
Date Revised 02.12.2022 published: Electronic-eCollection ClinicalTrials.gov: NCT03539224 Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1093/ofid/ofac610 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM349604193 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM349604193 | ||
| 003 | DE-627 | ||
| 005 | 20231226043027.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/ofid/ofac610 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1165.xml |
| 035 | |a (DE-627)NLM349604193 | ||
| 035 | |a (NLM)36447613 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a De Miguel Buckley, Rosa |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Long-term Evaluation of Residual Viremia in a Clinical Trial of Dolutegravir Plus Lamivudine as Maintenance Treatment for Participants With and Without Prior Lamivudine Resistance |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 02.12.2022 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a ClinicalTrials.gov: NCT03539224 | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America. | ||
| 520 | |a In this pilot clinical trial, we evaluated rates of residual replication in persons without lamivudine resistance-associated mutations in proviral DNA population sequencing who switched to dolutegravir plus lamivudine. After 144 weeks, there was no signal of changes in residual viremia based on qualitative detection methods, irrespective of past lamivudine resistance. Clinical Trials Registration. NCT03539224 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a HIV | |
| 650 | 4 | |a M184V/I | |
| 650 | 4 | |a dolutegravir plus lamivudine | |
| 650 | 4 | |a lamivudine resistance | |
| 650 | 4 | |a next-generation sequencing | |
| 650 | 4 | |a residual viremia | |
| 650 | 4 | |a virologically suppressed | |
| 700 | 1 | |a Rial-Crestelo, David |e verfasserin |4 aut | |
| 700 | 1 | |a Montejano, Rocío |e verfasserin |4 aut | |
| 700 | 1 | |a Pinto, Adriana |e verfasserin |4 aut | |
| 700 | 1 | |a Jimenez-Gonzalez, María |e verfasserin |4 aut | |
| 700 | 1 | |a Lagarde, Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Esteban-Cantos, Andrés |e verfasserin |4 aut | |
| 700 | 1 | |a Aranguren-Rivas, Paula |e verfasserin |4 aut | |
| 700 | 1 | |a Cadiñanos, Julen |e verfasserin |4 aut | |
| 700 | 1 | |a Bisbal, Otilia |e verfasserin |4 aut | |
| 700 | 1 | |a Castro, Juan Miguel |e verfasserin |4 aut | |
| 700 | 1 | |a Santacreu-Guerrero, Mireia |e verfasserin |4 aut | |
| 700 | 1 | |a Bermejo-Plaza, Laura |e verfasserin |4 aut | |
| 700 | 1 | |a Moreno, Victoria |e verfasserin |4 aut | |
| 700 | 1 | |a Hernando, Asunción |e verfasserin |4 aut | |
| 700 | 1 | |a Martín-Carbonero, Luz |e verfasserin |4 aut | |
| 700 | 1 | |a Rubio, Rafael |e verfasserin |4 aut | |
| 700 | 1 | |a Delgado, Rafael |e verfasserin |4 aut | |
| 700 | 1 | |a Arribas, José Ramón |e verfasserin |4 aut | |
| 700 | 1 | |a Pulido, Federico |e verfasserin |4 aut | |
| 700 | 0 | |a Antiretroviral Treatment Guided by Proviral Genotype (ART-PRO) Study Group |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Open forum infectious diseases |d 2014 |g 9(2022), 11 vom: 01. Nov., Seite ofac610 |w (DE-627)NLM243576811 |x 2328-8957 |7 nnns |
| 773 | 1 | 8 | |g volume:9 |g year:2022 |g number:11 |g day:01 |g month:11 |g pages:ofac610 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/ofid/ofac610 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 9 |j 2022 |e 11 |b 01 |c 11 |h ofac610 | ||